ArticleClinicoEconomics and outcomes research : CEOR2017

Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.

Marek Psota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.